What is the recommended dosing, contraindications, monitoring, and alternative therapies for Arcalyst (rilonacept)?

Arcalyst (Rilonacept): Dosing, Contraindications, Monitoring, and Alternatives

Recommended Dosing

Arcalyst dosing varies by indication and is administered subcutaneously once weekly 1.

For CAPS (FCAS and MWS) and Recurrent Pericarditis:

Adults:

• Loading dose: 320 mg delivered as two 160 mg (2 mL) injections on the same day at different sites
• Maintenance dose: 160 mg (2 mL) once weekly 1

Pediatric patients (12-17 years):

• Loading dose: 4.4 mg/kg (maximum 320 mg) as 1-2 injections (max 2 mL per site)
• Maintenance dose: 2.2 mg/kg (maximum 160 mg) once weekly 1

This aligns with the 2022 EULAR/ACR guidelines which recommend the same dosing regimen for CAPS 2.

For DIRA (Deficiency of IL-1 Receptor Antagonist):

Adults and pediatric patients ≥10 kg:

• 4.4 mg/kg (maximum 320 mg) once weekly as 1-2 injections (max 2 mL per site) 1
• No loading dose required for DIRA 2

Administration Details:

• Reconstitute each 220 mg vial with 2.3 mL preservative-free Sterile Water for Injection to yield 80 mg/mL solution
• Use reconstituted solution within 3 hours; protect from light
• Rotate injection sites (abdomen, thigh, upper arm); avoid bruised, red, tender, or hard areas
• If a dose is missed within 7 days, administer and resume original schedule; if >7 days, administer and start new schedule 1

---

Contraindications

There are no absolute contraindications listed in the FDA label 1.

However, do not initiate Arcalyst in patients with active or chronic infections due to the risk of serious, life-threatening infections associated with IL-1 blockade 1. This is a critical safety consideration rather than a formal contraindication.

---

Monitoring Parameters

Before Initiating Treatment:

• Screen for active infections (bacterial, viral, fungal, tuberculosis)
• Update vaccinations per current guidelines; avoid live vaccines during treatment 1
• Baseline inflammatory markers: C-reactive protein (CRP) - target <5-10 mg/L for adequate disease control 2

During Treatment:

• Clinical symptoms: Monitor daily symptom scores or Autoinflammatory Diseases Activity Index (AIDAI), Physician Global Assessment (PGA), and Patient/Parent Global Assessment (PPGA) 2
• CRP levels: Aim for normalization (<5-10 mg/L) to assess disease control 2
• Infection surveillance: Monitor for signs/symptoms of serious infections; discontinue if serious infection develops 1
• Injection site reactions: Most common adverse effect; typically mild 3, 4
• Upper respiratory tract infections: Most frequent infectious adverse event 1

Treatment Goals:

Achieve remission defined as absence of clinical symptoms and normal inflammatory markers 2. For recurrent pericarditis specifically, median time to pain response is 5 days and CRP normalization is 7 days 3, 4.

Treat-to-Target Strategy:

Adjust dose/frequency to achieve low disease activity with normalized inflammatory markers. Most patients require continuous administration, though some may achieve remission allowing for tapering 2.

---

Alternative Therapies

For CAPS (FCAS/MWS):

First-line IL-1 inhibitors:

1. Canakinumab (FDA and EMA approved):

   • Pediatric: 2-8 mg/kg every 8 weeks
   • Adults >40 kg: 150-600 mg every 8 weeks
   • Level of Evidence: 1B 2

2. Anakinra (EMA approved for CAPS):

   • 1-2 mg/kg/day (daily subcutaneous injection)
   • Level of Evidence: 4C for FCAS, 2B for MWS 2
   • Advantage: Daily dosing allows rapid titration; disadvantage: daily injections vs. weekly rilonacept 5

The 2024 EULAR/PRES guidelines recommend initiating IL-1 or IL-6 inhibitors as early as possible when diagnosis is established, ideally within 3 months of symptom onset to prevent chronic disease 6.

For Recurrent Pericarditis:

Standard background therapy (before biologics):

• NSAIDs (symptomatic relief during diagnostic workup only) 6
• Colchicine (halves recurrence rate; should be first-line) 7
• Glucocorticoids (use sparingly; associated with higher recurrence rates)

IL-1 inhibitors:

1. Anakinra (off-label):

   • 1-2 mg/kg/day (100 mg/day typical adult dose)
   • Incidence of serious adverse events: 10.4 per 100 patient-years
   • Infectious SAEs: 3.2 per 100 patient-years 6

2. Rilonacept (FDA approved):

   • Incidence of serious adverse events: 14.6 per 100 patient-years
   • Infectious SAEs: 3.9 per 100 patient-years
   • Advantage: Weekly dosing improves adherence and quality of life 7

IL-6 inhibitor:

• Tocilizumab (off-label for Still's disease/refractory cases):
  • Higher rate of serious adverse events (36.5 per 100 patient-years) and infectious AEs (104.6 per 100 patient-years) compared to IL-1 inhibitors 6

For DIRA:

Anakinra is the primary alternative:

• 1-8 mg/kg/day (FDA approved)
• Level of Evidence: 4C 2

---

Key Clinical Pearls

Safety Profile:

Rilonacept demonstrates a reassuring safety profile with the most common adverse events being injection site reactions and upper respiratory infections 6, 3, 4. Only one serious adverse event led to discontinuation in the phase II recurrent pericarditis trial 4.

Glucocorticoid Tapering:

All patients receiving rilonacept in clinical trials were successfully weaned off background therapy, including glucocorticoids 3, 4. In the phase II trial, 84.6% of patients on corticosteroids at baseline discontinued them completely, with 2 patients tapering successfully 4.

Treatment Duration:

Maintain clinical remission for 3-6 months without glucocorticoids before attempting biologic tapering 6. Withdrawal of glucocorticoids is mandatory before considering rilonacept dose reduction.

Common Pitfalls:

• Delaying IL-1 inhibitor initiation: Early treatment (within 3 months) prevents chronic persistent disease and improves long-term outcomes 6
• Inadequate infection screening: Always screen for active infections before starting; IL-1 blockade increases infection risk 1
• Premature biologic tapering: Ensure sustained remission off glucocorticoids before considering rilonacept dose reduction 6